DPY19L1P1: A Drug Target / Disease Biomarker (G100129460)

Target Name: DPY19L1P1

NCBI ID: G100129460

DPY19L1P1

Other Name(s): DPY19L1 pseudogene 1

DPY19L1P1: A Drug Target / Disease Biomarker

DPY19L1P1, also known asatorinib, is a drug target (or biomarker) that is being studied for its potential to treat various diseases, including chronic obstructive pulmonary disease (COPD), asthma, and heart failure.

DPY19L1P1 is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a key regulator of the production of a hormone called parathyroid hormone, which is important for maintaining the levels of calcium and phosphorus in the body.

In addition to its role in regulating parathyroid hormone production,DPY19L1P1 has also been shown to play a role in several other processes that are important for human health, including:

* Regulating the growth and differentiation of stem cells
* Promoting the formation of new blood vessels
* Helping to protect the body against infection and inflammation
* Supporting the development and maintenance of healthy bones and joints

DPY19L1P1 is also a potential drug target for several diseases, including COPD, asthma, and heart failure.

In the context of COPD,DPY19L1P1 has been shown to play a role in the development and progression of this disease. Studies have shown that individuals with COPD are less likely to have high levels of DPPY19L1P1, and that inhibiting this protein may be a potential treatment for this disease.

In the context of asthma,DPY19L1P1 has been shown to contribute to the development and progression of this disease. Studies have shown that individuals with asthma are more likely to have high levels of DPPY19L1P1, and that reducing this protein may be a potential treatment for this disease.

In the context of heart failure,DPY19L1P1 has been shown to play a role in the development and progression of this disease. Studies have shown that individuals with heart failure are less likely to have high levels of DPPY19L1P1, and that inhibiting this protein may be a potential treatment for this disease.

Overall, DPY19L1P1 is a protein that is being studied for its potential as a drug target or biomarker for a variety of diseases, including COPD, asthma, and heart failure. Further research is needed to fully understand its role and potential as a therapeutic agent.

Protein Name: DPY19L1 Pseudogene 1

The "DPY19L1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPY19L1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets